Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: An observational, multicentre cohort study

The Lancet Infectious Diseases

Volumn 11, Issue 3, 2011, Pages 181-189

  Kett, Daniel H ^a   Cano, Ennie ^a   Quartin, Andrew A ^a   Mangino, Julie E ^b   Zervos, Marcus J ^c   Peyrani, Paula ^d   Cely, Cynthia M ^a   Ford, Kimbal D ^e   Scerpella, Ernesto G ^e   Ramirez, Julio A ^d  

^a UNIVERSITY OF MIAMI   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL TIME; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ADULT; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952041221     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70314-5     Document Type: Article

References (34)

1. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162:185-190.
2. Dupont H, Mentec H, Sollet JP, Bleichner G Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001, 27:355-362.
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751.
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
5. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268.
6. Kollef MH Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31(suppl 4):S131-S138.
7. Kollef MH, Sherman G, Ward S, Fraser VJ Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
8. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
9. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004, 53:1-36.
10. Alvarez-Lerma F Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996, 22:387-394.
11. Kollef MH, Ward S The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420.
12. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008, 134:963-968.
13. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society, Infectious Diseases Society of AmericaInfectious Diseases Society of America.
14. Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997, 17:277-281.
15. Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994, 154:878-884.
16. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other infective agents. N Engl J Med 1998, 338:232-238.
17. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.
18. Leibovici L, Gitelman V, Yehezkelli Y, et al. Improving empirical antibiotic treatment: prospective, nonintervention testing of a decision support system. J Intern Med 1997, 242:395-400.
19. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
21. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
22. Social Security death index (accessed Nov 1, 2009). http://ssdi.rootsweb.ancestry.com.
23. Venkataraman R, Kellum JA Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007, 22:187-193.
24. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328:668.
25. Heyland DK, Dodek P, Muscedere J, Day A, Cook D Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744. Canadian Critical Care Trials Group.
26. Aarts M-AW, Hancock JN, Heyland D, McLeod RS, Marshall JC Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008, 36:108-117.
27. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005, 41:149-158.
28. Micek ST, Ward S, Fraser VJ, Kollef MH A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
29. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288:2859-2867.
30. Leijten FS, De Weerd AW, Poortvliet DC, De Ridder VA, Ulrich C, Harink-De Weerd JE Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996, 22:856-861.
31. Leijten FS, Harinck-de Weerd JE, Poortvliet DC, de Weerd AW The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995, 274:1221-1225.
32. Falagas ME, Kasiakou SK Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27.
33. Cohen JS Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001, 35:1540-1547.
34. Falagas ME, Rafailidis PI, Rosmarakis ES Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007, 29:374-379.